GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Deutetrabenazine tablets (Austedo / Austedo XR)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Austedo - labeled renal guidance

Product / population
Deutetrabenazine (Austedo), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 36, posted Oct 16, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Austedo - product and source limitations

The cited pharmacokinetic gap supplies no renal dose or dialysis timing rule. Confirm immediate- or extended-release instructions.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Austedo - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Deutetrabenazine (Austedo), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 36, posted Oct 16, 2026
Retrieved: 2026-11-07

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 12.3 Pharmacokinetics

No clinical study evaluated the effect of renal impairment on deutetrabenazine or its main metabolites. The cited pharmacokinetic gap supplies no renal dose or dialysis timing rule. Confirm immediate- or extended-release instructions.

RDM74-austedo-official-1 · Source locator: Renal guidance: 12.3 Pharmacokinetics

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 36, posted Oct 16, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
0f3913fa83f16a1ca4187ff45dbde0b65dc796637e7b1929e1c291889d631792

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=deutetrabenazine-austedo&s1=RDM74-austedo-official&h1=9a85c65549528cec235d36c9e1ef7081318e3046ffd02660bdef4c760183ed83

Top